Trials / Terminated
TerminatedNCT00100828
Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer
Phase II Trial of Irinotecan for Treatment of Metastatic Medullary Thyroid Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
- Sex
- All
- Age
- 18 Years – 120 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well irinotecan works in treating patients with metastatic or inoperable thyroid cancer.
Detailed description
OBJECTIVES: Primary * Determine the response rate in patients with metastatic or inoperable locoregional medullary thyroid cancer treated with irinotecan. Secondary * Determine the safety and tolerability of this drug in these patients. OUTLINE: Patients receive irinotecan IV on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Response is assessed after completion of 4 courses. Patients achieving complete response (CR) or partial response (PR) receive 2 additional courses beyond CR or PR. Patients who have stable disease receive up to 12 total courses. PROJECTED ACCRUAL: A total of 33 patients will be accrued for this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | irinotecan hydrochloride |
Timeline
- Start date
- 2004-11-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2005-01-07
- Last updated
- 2018-12-06
- Results posted
- 2018-12-06
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00100828. Inclusion in this directory is not an endorsement.